4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001628280-26-036885
Chief Executive Officer sold 15,000 shares at an average $20.04 ($300,579)
- Chief Executive Officer acquired 15,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire Chief Executive Officer | 2026-05-18 | Option exercise 10b5-1 | +15,000 | $3.79 | $56,847 | 377,152 | D |
| Mazumdar Claire Chief Executive Officer | 2026-05-18 | Sale 10b5-1 | −12,022 | $19.96 | $239,982 | 365,130 | D |
| Mazumdar Claire Chief Executive Officer | 2026-05-18 | Sale 10b5-1 | −2,978 | $20.35 | $60,597 | 362,152 | D |
| Derivatives | |||||||
| Mazumdar Claire Chief Executive Officer | 2026-05-18 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 146,107 | D | ||
| Open-market sales · 15,000 sh · avg $20.04 · $300,579 | |||||||
Loading xslF345X06/wk-form4_1779307664.xml…